Traumatic spinal cord injury (SCI) is a serious neurologic disorder that can result in long-term motor and sensory impairments after external damage to the spinal cord. Although anatomic MRI offers ...
Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...
Dr. David Nathanson is a professor of molecular and medical pharmacology at UCLA. He received his Ph.D. in molecular and medical pharmacology at UCLA under Dr. Paul Mischel, where he discovered that ...
Although absent in most adult tissues, hexokinase 2 (HK2) is expressed in most tumors and contributes to increased glucose consumption and to in vivo tumor 18F-FDG PET signaling. Methods: Both HK2 ...
A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET imaging followed by ...
Journal of Nuclear Medicine January 2026, jnumed.125.271410; DOI: https://doi.org/10.2967/jnumed.125.271410 ...
This paper presents standardized methods for collecting data to be used in performing dose calculations for radiopharmaceuticals. Various steps in the process are outlined, with some specific examples ...
Journal of Nuclear Medicine January 2026, jnumed.125.271020; DOI: https://doi.org/10.2967/jnumed.125.271020 ...
The principle of pretargeted radioimmunoimaging and therapy has been investigated over the past 30 y in preclinical and clinical settings with the aim of reducing the radiation burden of healthy ...
The evolution of peptidomimetic hybrid molecules for preoperative imaging and guided surgery targeting the prostate-specific membrane antigen (PSMA) significantly progressed over the past few years, ...
Radiolabeled fibroblast activation protein (FAP) inhibitors (FAPIs) have shown promise as cancer diagnostic agents; however, the relatively short tumor retention of FAPIs may limit their application ...
WHY IS FAP-TARGETED THERAPY ATTRACTIVE? FAP-positive CAFs are found in more than 90% of epithelial cancers, therefore representing a potential pan-cancer target (6). Targeting FAP to deplete stromal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results